Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNK-UT009
- Development stage
- Phase 1
- Lead developer
- ST Phi Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CNK-UT009 is an autologous chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of Type 1 Diabetes (T1D). The therapy involves engineering a patient's own T cells to express a chimeric antigen receptor that targets NKG2D ligands (NKG2D-L), including MICA, MICB, and several members of the UL16-binding protein (ULBP) family. These ligands are typically upregulated on the surface of autoreactive T cells that are responsible for the autoimmune destruction of insulin-producing pancreatic beta cells. By selectively targeting and depleting these pathogenic immune cells, CNK-UT009 aims to halt the progression of the disease, preserve remaining beta cell function, and restore or maintain endogenous insulin secretion. It is currently undergoing early-phase clinical evaluation to determine its safety, maximum tolerated dose, and preliminary metabolic efficacy.
- Other names
- CNK-UT009 cell injectionCNK-UT-009 cell injectionCNK-UT 009 cell injection
02
Targets
MICA (Major histocompatibility complex class I-related protein A)ULBP1 (UL16-binding protein 1)ULBP2 (UL16-binding protein 2)ULBP6 (UL16-binding protein 6)ULBP5 (UL16-binding protein 5)ULBP3 (UL16 binding protein 3)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on CNK-UT009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNK-UT009.